Interleukin-3 and interleukin-7 are alternative growth factors for the same B-cell precursors in the mouse.
Clones and lines of precursor (pre) B cells can be established by limiting dilutions of unseparated cell suspensions of fetal liver or bone marrow on stromal cells in the presence of interleukin (IL)-7. When IL-3 is used instead of IL-7, cultures are regularly overgrown by different precursor cells of the myeloid lineage, as well as by adherent cells that inhibit pre-B-cell expansion. However, in the presence of either IL-7 or IL-3, clones of pre-B cells can be established on stroma cells at frequencies near one in one when the cultures are initiated with cell sorter purified CD45RO (B220)+/c-kit+ fetal liver or bone marrow derived pre-B cells. Clones grown on stromal cells in the presence of IL-7 can be regrown in IL-3, and vice versa. Pre-B cells that proliferate on stromal cells in the presence of IL-7 or IL-3 have the same phenotype, ie, are B220+ c-kit+, CD43+, and surrogate light chain+. Removal of the growth factors (IL-7, respectively IL-3) from the cultures results in differentiation to surface immunoglobulin (slg) positive, c-kit-, CD43-, surrogate light chain- B cells, a fraction of which is lipopolysaccharide (LPS) responsive as shown by IgM secretion. These results show that IL-7 and IL-3 stimulate largely overlapping populations of precursor B cells from bone marrow to proliferate for long periods of time in the presence of stromal cells. Thus, IL-7 and IL-3 are alternative growth factors for the same pre-BI cell.
Winkler
T H
TH
Basel Institute for Immunology, Switzerland.
Melchers
F
F
Rolink
A G
AG
D000818:Animals; D015703:Antigens, CD; D000954:Antigens, Surface / Q000032:analysis; D001402:B-Lymphocytes / Q000166:cytology*; D001854:Bone Marrow Cells; D002454:Cell Differentiation; D002455:Cell Division; D002469:Cell Separation; D002478:Cells, Cultured; D003239:Connective Tissue Cells; D006410:Hematopoiesis / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D007075:Immunoglobulin M / Q000096:biosynthesis; D016130:Immunophenotyping; D007377:Interleukin-3 / Q000494:pharmacology / Q000502:physiology*; D015851:Interleukin-7 / Q000494:pharmacology / Q000502:physiology*; D017493:Leukocyte Common Antigens; D051917:Leukosialin; D008070:Lipopolysaccharides / Q000494:pharmacology; D008099:Liver / Q000196:embryology; D008213:Lymphocyte Activation; D051379:Mice / Q000502:physiology*; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D011518:Proto-Oncogene Proteins / Q000032:analysis; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis; D016184:Receptors, Colony-Stimulating Factor / Q000032:analysis; D012795:Sialoglycoproteins / Q000032:analysis
D015703:Antigens, CD; D000954:Antigens, Surface; D007075:Immunoglobulin M; D007377:Interleukin-3; D015851:Interleukin-7; D051917:Leukosialin; D008070:Lipopolysaccharides; D011518:Proto-Oncogene Proteins; D016184:Receptors, Colony-Stimulating Factor; D012795:Sialoglycoproteins; C497863:Spn protein, mouse; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases; D017493:Leukocyte Common Antigens